Embryo Appearance vs Genetic Test Results: Why Morphology and PGT Can Tell Different Stories

An embryologist looking down a microscope and a genetics laboratory reading a biopsy sample are answering two different questions. Morphology asks, “How does this embryo look and how is it developing?” PGT asks, “What do the chromosomes in this small sample look like?” Neither answer is a complete description of the embryo, and that is the main reason the two can seem to disagree.

If you have been given a high morphology grade alongside an abnormal PGT-A result — or the reverse — this guide explains the layers of information separately, then shows how they are usually weighed together in a conversation with your treating clinician.

What a morphology grade actually describes

Morphology is a visual assessment made at a particular moment. For a blastocyst, embryologists typically comment on expansion, the number and tightness of cells in the inner cell mass, and the number and cohesion of cells in the trophectoderm (the outer layer that later forms the placenta). A grading system condenses these observations into a score.

Three features of morphology matter for interpretation:

• It is a snapshot. The embryo was observed at one time point; it continues to change in culture and, later, in the uterus.
• It is an appearance, not a measurement of chromosomes. Cell number, symmetry, fragmentation and expansion describe structure and developmental progress. They do not read the DNA inside those cells.
• It is a proxy. A good grade is associated with developmental potential in the aggregate, but it cannot confirm the chromosomal content of an individual embryo.

This is why morphology is best read as a description of how the embryo looks and is progressing, not as a verdict on its genetic makeup.

What PGT-A actually reports

PGT-A assesses chromosome number in cells sampled from an embryo. In a typical blastocyst biopsy, a few trophectoderm cells are removed and analysed, and the report describes chromosome copy-number findings for that sample.

The HFEA, the UK fertility regulator, notes that PGT-A has limitations and can produce incorrect findings, and that a result does not guarantee a successful pregnancy or a healthy child. Those two points are worth holding alongside any report you receive.

Several features of a PGT-A result shape how much it can tell you:

• It is a sample, not the whole embryo. The biopsy represents a small number of cells from one region. The ASRM committee opinion on mosaic PGT-A results notes that a sampled result does not establish the cell composition of the whole embryo.
• Mosaicism complicates the picture. A mosaic result is inferred from intermediate chromosome copy-number findings. ASRM notes that technical factors can contribute to such findings, and that results and relevant uncertainty should be discussed with the treating clinician and genetic counsellor.
• “No result” happens. Sometimes the sample does not yield enough interpretable information, and the laboratory cannot issue a clear finding. That is a limitation of the test, not a statement about the embryo’s health.
• Scope is limited. PGT-A looks at chromosome number. It does not screen for every possible genetic condition, and it is not the same test as PGT-M or PGT-SR.

Why a top-graded embryo can test aneuploid

This is the scenario that surprises patients most. An embryo can look textbook-perfect under the microscope and still carry an abnormal number of chromosomes, because chromosomal content is invisible to the eye. Cell division can proceed neatly while the chromosomes inside those dividing cells are misdistributed.

The reverse also occurs: an embryo with a lower morphology grade can test euploid (a normal chromosome number for the sample). A lower grade describes appearance and developmental pace; it does not by itself indicate a chromosomal abnormality.

Put simply, morphology and PGT-A are not two measurements of the same thing. One describes structure; the other describes a chromosome finding from a sample. Expecting them to agree is like expecting a photograph and a blood test to tell the same story.

Where interpretation gets harder: mosaicism and no-result reports

Not every PGT-A report is a clean “euploid” or “aneuploid.” Two categories deserve particular care.

Mosaic results

A mosaic result sits between the two poles: the sample shows an intermediate chromosome pattern rather than a uniform one. ASRM’s guidance emphasises that such findings are inferred from the biopsy and may be influenced by technical factors, and that the uncertainty should be discussed with your clinician and a genetic counsellor. A mosaic report is therefore a prompt for a careful conversation, not a simple label.

No-result reports

When a sample cannot be interpreted, the laboratory may report that no result was obtained. This says something about the test’s technical limits, not about the embryo’s chromosomes. Your clinic can explain what options exist in that situation, which may include further discussion rather than an automatic decision.

PGT-A is not the only genetic test — and the questions differ

It helps to separate the PGT family, because each addresses a different question:

Test	Question it addresses
PGT-A	Chromosome number in sampled cells
PGT-M	A known monogenic (single-gene) condition in the family
PGT-SR	Chromosomal structural rearrangements

The HFEA describes PGT-M as concerning a known monogenic condition and PGT-SR as concerning chromosomal structural rearrangements, noting that these tests address different questions and that a treating team and genetic counsellor should discuss the relevant history, test design and suitability. None of these tests is a guarantee, and none is automatically appropriate for every patient; suitability is a clinical judgement.

Bringing both reports into one conversation

Morphology and PGT results are usually considered together, alongside your history, age, the number of embryos available and your own priorities. How much weight each piece carries is a clinical decision your treating team makes with you — not something a report decides on its own.

Before a consultation, it can help to gather both reports and note the date of each, so the discussion starts from the same documents. Useful questions for your clinician include:

• Which information would most influence a transfer decision in my case, and why?
• How should I understand this specific morphology grade alongside this specific PGT result?
• If the result is mosaic or shows no result, what does that mean for my options, and what would you recommend discussing next?
• What are the alternatives to using PGT in my situation, and what are their trade-offs?
• What does the test not tell us?

These are clinical questions, and your treating clinician and a genetic counsellor are the right people to answer them. A coordination service can help you organise records and prepare questions, but it does not interpret results or recommend treatment.

A practical way to hold the two kinds of information

When you read your reports, it can help to keep three columns in mind: what was observed (morphology), what was sampled and found (PGT), and what remains uncertain (mosaicism, no result, test limits). Writing these out before an appointment often makes the conversation clearer and helps you notice which questions are still open.

If you are comparing clinics or laboratories, it is reasonable to ask how each explains its reports and what counselling is available. A neutral starting point is our guide to reading PGT-A results, and for laboratory questions, the checklist on verifying a fertility clinic’s genetics laboratory. If you are weighing whether testing fits your situation at all, see whether PGT is worth it, and for mosaic findings specifically, what mosaic embryo results mean.

The short answer to the original question: morphology and PGT describe different layers of the same embryo, each with its own limits. Disagreement between them is not a contradiction to resolve, but information to discuss.